Entecavir (ETV) Is Superior to Lamivudine and Adefovir in Trials of HBeAg Positive and Negative?Chronic Hepatitis B Infection: A Cross-study Analysis with Published Reports?br>
?span style='font:7.0pt "Times New Roman"'> ETV was superior to adefovir/ADV (Hepsera) for all efficacy measures in HBeAg+ patients and virologic endpoints in HBeAg- patients? (other endpoints comparable).?
?span style='font:7.0pt "Times New Roman"'> Lamivudine/LVD (Epivir-HBV) was superior to ADV in HBeAg+ patients for all efficacy measures except ≥2 point histologic activity index improvement and ranked assessment of necrosis/inflammation (NI), and in HBeAg- patients for virologic endpoints (other endpoints comparable).?
?span style='font:7.0pt "Times New Roman"'> ETV was superior to LVD for all efficacy measures except ranked assessment of NI and fibrosis (HBeAg+/-), and HBeAg+ seroconversion (other endpoints comparable).
For virologic endpoints, ETV is superior to LVD, which is superior to ADV.?Based upon controlled trials of ETV and LVD and analyses of multiple studies in which LVD and ADV were analyzed individually, ETV consistently ranks highest among the three drugs across multiple endpoints for both HBeAg+ and HBeAg- patients with chronic hepatitis B.牋
Reference
J L Dienstag and others. Abstract 481. 40th EASL. April 13-17, 2005. Paris, France.?/font> | 
发表于 2005-4-24 23:45
